<DOC>
	<DOCNO>NCT01174160</DOCNO>
	<brief_summary>This study investigate treatment vernakalant hydrochloride ( MK-6621 ) result great proportion patient treatment-induced conversion Atrial Fibrillation sinus rhythm compare placebo .</brief_summary>
	<brief_title>A Study Efficacy Safety Vernakalant Hydrochloride ( MK-6621 ) Patients With Atrial Fibrillation ( MK-6621-010 AM4 )</brief_title>
	<detailed_description>Amendment 4 protocol revise plan enrollment 123 participant remove China one country participate study .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Abstinent willing use 2 acceptable method birth control Patient atrial arrhythmia dysrhythmic symptom Patient receive adequate anticoagulant therapy Patient stable blood pressure Patient weigh 45 136 kg ( 99 300 lb ) Patient adequately hydrate Patient pregnant , breastfeeding , expect become pregnant study Patient routinely consume 2 alcoholic drink per day Patient know suspect prolonged QT , familial long QT syndrome , previous Torsades de Pointes , Brugada syndrome Patient know bradycardia , advance AV block , sicksinus syndrome , unless control pacemaker Patient severe aortic stenosis Patient atrial flutter Patient Class IV congestive heart failure ( CHF ) Patient myocardial infarction ( MI ) acute coronary syndrome ( ACS ) Patient cardiac surgery within 30 day Patient know atrial thrombus Patient reversible cause Atrial Fibrillation Patient fail electrical cardioversion current episode Atrial Fibrillation Patient uncorrected electrolyte imbalance Patient clinical evidence digoxin toxicity Patient receive certain antiarrhythmic drug intravenous amiodarone within 7 day Patient know HIV positive Patient history cancer within past 5 year , except certain skin cervical cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
</DOC>